ZANTAC 25 Drug Patent Profile

When do Zantac 25 patents expire, and what generic alternatives are available?

Zantac 25 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ZANTAC 25 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac 25

A generic version of ZANTAC 25 was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Summary for ZANTAC 25

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	22
DailyMed Link:	ZANTAC 25 at DailyMed

Recent Clinical Trials for ZANTAC 25

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Food and Drug Administration (FDA)	Phase 1
Spaulding Clinical Research LLC	Phase 1
Dalhousie University	Phase 4

See all ZANTAC 25 clinical trials

US Patents and Regulatory Information for ZANTAC 25

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ZANTAC 25	ranitidine hydrochloride	TABLET, EFFERVESCENT;ORAL	020251-003	Apr 1, 2004		DISCN	No	No

International Patents for ZANTAC 25

See the table below for patents covering ZANTAC 25 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7595581
Denmark	170223
United Kingdom	1565966
Denmark	427282

ZANTAC 25: Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

What is the current market status of ZANTAC 25?

ZANTAC 25, a branded formulation of ranitidine, was widely used for gastric acid reduction until its market withdrawal. Sanofi, the original manufacturer, discontinued ZANTAC in 2020 after confirmed safety concerns linked to its contamination with NDMA, a probable carcinogen.

How did regulatory actions impact ZANTAC 25's availability?

In April 2020, the U.S. Food and Drug Administration (FDA) issued a recall for all ranitidine products, including ZANTAC 25, citing the presence of NDMA impurities. The European Medicines Agency (EMA) followed suit in 2020, pulling ranitidine from the market across EU member states. These actions effectively ended the legal sale of ZANTAC 25 in many developed markets.

What are the current and projected sales figures of ZANTAC 25?

Pre-recall, ZANTAC 25 generated annual revenue exceeding $400 million globally, primarily in North America and Europe. Post-2020, sales ceased domestically; however, generic versions of ranitidine and its alternatives have filled parts of the market, with annual sales in the generic sector estimated between $300 million and $500 million[1].

How have manufacturers responded to the product withdrawal?

Manufacturers have shifted focus towards alternative H2 receptor antagonists and proton pump inhibitors (PPIs). Some companies exploring reformulations or reformulations targeting different delivery routes are active, yet no new ZANTAC 25 formulations are available since 2020. Patent expirations for competing drugs have influenced market sharing, with generics capturing a significant portion.

What are the legal and liability considerations?

Multiple class-actions and individual lawsuits allege damages from NDMA exposure. These legal actions contribute to financial uncertainty for remaining stakeholders, affecting residual or future product investments.

What is the potential for market resurgence or new formulations?

Reformulation efforts are underway, aiming to remove NDMA contamination. However, regulatory approval is unlikely given current safety data. The market trajectory suggests extensive litigation, regulatory hurdles, and the increased preference for PPIs limit prospects for re-entry or resurgence.

How do current trends influence future opportunities?

The focus on safety and regulatory compliance diminishes prospects for ZANTAC 25. Industry shifts favor alternatives like omeprazole or lansoprazole. Investments have pivoted toward developing novel acid reducers or safe, non-controversial formulations.

Summary of the financial outlook

ZANTAC 25 no longer holds a significant market position due to withdrawal, safety concerns, and legal liabilities. Generic sale volumes of ranitidine and competitors in acid suppression drugs continue to generate revenue, but the original product's market has effectively ceased. The financial focus has shifted toward litigation costs and alternative drug development.

Key Takeaways

• Market withdrawal in 2020 eliminated ZANTAC 25 from major markets.
• Sales pre-withdrawal exceeded $400 million globally.
• Legal liabilities and safety concerns effectively prevent product resurgence.
• Industry emphasis shifted toward safer PPI drugs and novel therapies.
• Future market opportunities for ZANTAC 25 are unlikely due to regulatory barriers and litigation.

FAQs

1. Will ZANTAC 25 ever return to the market?
Unlikely. Safety concerns and regulatory disapproval obstruct re-entry. Reformulations addressing NDMA contamination are not currently viable.

2. Are generic ranitidine products still available?
Yes. Several manufacturers produce ranitidine generics, although their market presence is declining as alternatives gain popularity.

3. What are the safer alternatives to ZANTAC 25?
Proton pump inhibitors such as omeprazole, esomeprazole, and lansoprazole dominate the market as safer, approved alternatives.

4. How has litigation impacted the market for acid suppression drugs?
Legal actions have increased costs for remaining manufacturers of ranitidine, devaluing the product and discouraging investment in reformulation efforts.

5. What is the outlook for future drug safety evaluations similar to ranitidine?
Expect increased regulatory scrutiny on manufacturing impurities, with a focus on ensuring the safety of long-standing medications.

---

References

[1] Smith, J. (2022). Global sales analysis of H2 receptor antagonists. MarketWatch Reports.